IDEXX Laboratories stock

IDXX · NASDAQ · USD

$704.23Change from previous close: +0.89%Absolute change: +$6.21

Close · November 13, 2026

Price history

+0.39% over the period

1 year: from $701.48 (November 13, 2025) to $704.23 (November 13, 2026), +0.39%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$704.23
October 30, 2026$551.21
September 30, 2026$522.19
August 31, 2026$556.69
July 31, 2026$559.07
June 30, 2026$526.44
May 29, 2026$563.53
April 30, 2026$560.80
March 31, 2026$561.89
February 27, 2026$656.73
January 30, 2026$670.46
December 31, 2025$676.53
November 28, 2025$752.88
November 13, 2025$701.48

At a glance

  • The company

    Develops, manufactures and distributes diagnostic products and software for companion animal, livestock, dairy and water testing markets

  • Latest results

    Quarter to September 30, 2026 · EPS $4.01 (estimate $3.72)

TickerLandia's take on IDEXX Laboratories

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$500.61
52-wk high$769.98

−8.54% from the 52-week high

Analysts · 14 analysts

Average target$717.17+1.84% vs. price

Buy 9 · Hold 4 · Sell 1 · Buy

TickerLandia Fingerprint: IDEXX Laboratories

Compared with similar companies: very high profitability and very high price.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

IDEXX Laboratories is priced as in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), IDEXX Laboratories's P/E today is 53.8, in line with the median of its last 10 fiscal years (52.5; between 38.7 and 76.6 from 2016 to 2025). IDEXX Laboratories's P/E (trailing 12 months): 47.0, +30% against the median of a group of 9 similar companies (36.1).

P/E compared with its history

Compared with 9 similar companies

IDEXX Laboratories's metrics compared with similar companies
MetricIDEXX LaboratoriesPosition in the groupBand
P/E (trailing 12 months)47.0High
Forward P/E41.7High
Operating margin32.5%High
ROE68.9%High
Debt/equity0.52Middle

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: IDEXX Laboratories. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$1.22B

Latest quarter · Q2 2026

Net income

$338.41M

Latest quarter · Q2 2026

Quarterly net margin

27.8%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$55.48B
P/E
47.0
EPS
$14.97
Volume
392.45K
Daily trading
€394.97M
Dividend yield
0.00%

How IDEXX Laboratories is changing

All results
  • Revenue grew 9.7% a year on average over the last 5 years

  • Operating margin rose from 26.7% to 31.6%

  • Profits turn into cash: free cash flow equal to 94% of net income

Returns

IDEXX Laboratories returns

$1,000 invested in IDEXX Laboratories 5 years ago, on November 15, 2021, would be worth $1,138 today: +13.78% in total, +2.62% per year. This is the price return only: dividends are excluded.

PeriodIDEXX LaboratoriesS&P 500$1,000 becomes
1 month+35.35%−3.12%$1,353
6 months+33.21%+1.58%$1,332
Year to date+4.09%+10.46%$1,041
1 year+0.39%+12.23%$1,004
3 years+62.87%+71.41%$1,629
5 years+13.78%+61.48%$1,138
10 years+544.31%+249.40%$6,443

Over the last 6 months it has done better than 71% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

IDEXX Laboratories: technical analysis

IDEXX Laboratories shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 8.1% below its all-time closing high ($766.68, November 25, 2025).

Trend
No clear trend
RSI (14 sessions)
72
Above 70: a strong rise in a short time
vs 200-session average
+23.04%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since November 2, 2026

Support and resistance

Price areas where IDEXX Laboratories has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$704.23
  3. Support$661.21−6.11%4 touches, last on February 26, 2026
  4. Support$621.17−11.79%3 touches, last on August 4, 2026
  5. Support$602.13−14.50%3 touches, last on April 17, 2026

Volatility and risk

Over the last year it has moved roughly in line with the S&P 500.

Beta (1 year) vs S&P 500
0.83
Volatility (60 sessions, annualised)
49.1%
Largest fall in the last year
−34.17%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

IDEXX Laboratories: seasonality

Average monthly price change over 36 years

+0.9%Jan+4.8%Feb−1.3%Mar+4.4%Apr+2.4%May+0.5%Jun+4.8%Jul+1.5%Aug+1.3%Sep+0.8%Oct+2.8%Nov+2.7%Dec

Over the last 36 years, the strongest month for IDEXX Laboratories has been February: +4.76% on average, positive in 22 years out of 35. The weakest has been March: −1.33% on average, positive in 19 years out of 35. November, the current month, has been positive in 22 years out of 35 (+2.82% on average).

Show chart data
MonthAverageMedianPositive years
January+0.94%+2.60%20 of 35
February+4.76%+2.29%22 of 35
March−1.33%+1.68%19 of 35
April+4.42%+4.15%26 of 35
May+2.35%+1.61%22 of 35
June+0.48%−1.47%16 of 35
July+4.76%+6.10%24 of 36
August+1.50%+0.42%18 of 36
September+1.33%+0.28%20 of 36
October+0.83%+2.65%19 of 36
November+2.82%+2.97%22 of 35
December+2.69%+2.35%20 of 35

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

IDEXX Laboratories and its competitors

Sales reach far beyond the United States, which accounts for 64% of revenue, while Europe, the Middle East and Africa represent 5.3%, and Germany, Canada, the United Kingdom, France and Australia each contribute between 2.6% and 4.8%. The company makes diagnostic instruments, test kits and reagents for veterinary clinics, livestock and poultry producers, dairy operations and water-testing laboratories. Its portfolio includes SNAP rapid test kits, blood and urine chemistry and hematology analyzers, and the Colilert family of tests for detecting total coliforms and E. coli in water.

Headquarters
Westbrook, United States
Employees
11,000
Founded
1983
Chief executive
Michael Erickson
IDEXX Laboratories and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
IDEXX LaboratoriesIDXX$55.48B32.5%47.0+33.21%
Agilent TechnologiesA$49.04B24.5%34.3+54.30%
NateraNTRA$46.27B-8.5%—+63.37%
IQVIA HoldingsIQV$43.69B13.9%32.3+53.80%
Mettler-Toledo InternationalMTD$34.59B27.8%37.7+69.56%
WatersWAT$90.45B16.0%192.6+37.42%

Same industry or related industries, similar size. Compare IDEXX Laboratories with its competitors · Full profile